Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
How should other medications be administered with Trulicity® (dulaglutide)?
Consider a reduction of insulin and/or sulfonylurea dose to address the risk of hypoglycaemia. Dulaglutide delays gastric emptying and can alter the absorption of oral medications with rapid absorption or prolonged release.
Relevant information from the summary of product characteristics
Patients receiving dulaglutide in combination with sulphonylurea or insulin may have an increased risk of hypoglycaemia. Additionally, dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products.1
For complete information, please refer to the Trulicity Summary of Product Characteristics, in particular the sections
- 4.2 Posology and method of administration
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.8 Undesirable effects
There is limited experience with the use of concomitant medications in clinical trials with dulaglutide doses of 3 mg and 4.5 mg.2
Potential for co-administered drugs to influence the pharmacokinetics of dulaglutide
Compared with dulaglutide being taken alone, the coadministration of a single dose of dulaglutide 1.5 mg with steady-state sitagliptin 100 mg resulted in increases for dulaglutide
- area under the time-concentration curve (AUC) by approximately 38%
- maximum observed drug concentration (Cmax) by approximately 27%, and
- median time to maximum concentration (Tmax) of approximately 24 hours.3
These differences in the pharmacokinetic profile are not considered clinically relevant.3
References
1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Geiser J, de la Peña A, Cui X, et al. No dose adjustment is needed when coadministering dulaglutide with once-daily sitagliptin. Poster presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting: March 15-18, 2017; Washington, D.C.
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
Date of Last Review: 30 March 2026